Recent Company News

• 05:30 PM ET Oct 31, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:42 PM ET Oct 31, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 2-Nov

• 12:20 PM ET Oct 31, 2025
  

  StreetAccount ESG Week Ahead: Nov 3rd - Nov 7th

• 08:54 AM ET Oct 31, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:05 PM ET Oct 30, 2025
  

  Daiichi Sankyo notes first patient dosed in ESTINY-Lung06 phase 3 trial of ENHERTU (¥3905.0000, +63)

• 01:12 PM ET Oct 29, 2025
  

  HHS issues press release on accelerating biosimilar drug development and lowering drug prices

• 09:21 AM ET Oct 29, 2025
  

  FDA announces draft guidance for biosimilar development

• 08:09 AM ET Oct 29, 2025
  

  AstraZeneca announces ENHERTU receives approval in Canada as HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer (12632.0000p, +226)

• 03:06 AM ET Oct 28, 2025
  

  AstraZeneca announces Koselugo has been approved in EU for plexiform neurofibromas in adults with neurofibromatosis type 1 (12546.0000p, 0)

• 05:24 PM ET Oct 27, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market